We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ginkgo Bioworks Holdings, Inc. (DNA) Advances While Market Declines: Some Information for Investors
Read MoreHide Full Article
Ginkgo Bioworks Holdings, Inc. (DNA - Free Report) ended the recent trading session at $12.35, demonstrating a +2.66% change from the preceding day's closing price. This move outpaced the S&P 500's daily loss of 0.55%. At the same time, the Dow lost 0.19%, and the tech-heavy Nasdaq lost 0.95%.
Shares of the company witnessed a loss of 0.17% over the previous month, beating the performance of the Medical sector with its loss of 0.2%, and underperforming the S&P 500's gain of 3.64%.
Analysts and investors alike will be keeping a close eye on the performance of Ginkgo Bioworks Holdings, Inc. in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of -$1.24, marking a 14.81% fall compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $39 million, down 56.2% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates project earnings of -$5.27 per share and a revenue of $181 million, demonstrating changes of +49.13% and -20.28%, respectively, from the preceding year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Ginkgo Bioworks Holdings, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. At present, Ginkgo Bioworks Holdings, Inc. boasts a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 102, putting it in the top 42% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ginkgo Bioworks Holdings, Inc. (DNA) Advances While Market Declines: Some Information for Investors
Ginkgo Bioworks Holdings, Inc. (DNA - Free Report) ended the recent trading session at $12.35, demonstrating a +2.66% change from the preceding day's closing price. This move outpaced the S&P 500's daily loss of 0.55%. At the same time, the Dow lost 0.19%, and the tech-heavy Nasdaq lost 0.95%.
Shares of the company witnessed a loss of 0.17% over the previous month, beating the performance of the Medical sector with its loss of 0.2%, and underperforming the S&P 500's gain of 3.64%.
Analysts and investors alike will be keeping a close eye on the performance of Ginkgo Bioworks Holdings, Inc. in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of -$1.24, marking a 14.81% fall compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $39 million, down 56.2% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates project earnings of -$5.27 per share and a revenue of $181 million, demonstrating changes of +49.13% and -20.28%, respectively, from the preceding year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Ginkgo Bioworks Holdings, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. At present, Ginkgo Bioworks Holdings, Inc. boasts a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 102, putting it in the top 42% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.